Regenxbio (RGNX) Operating Margin (2014 - 2025)
Regenxbio (RGNX) recorded quarterly Operating Margin of 189.99% in Q4 2025, down 7.78% quarter-over-quarter from 176.27% in Q3 2025, and up 5216.0% on a YoY basis from 3.57% in Q4 2024.
Regenxbio (RGNX) Operating Margin (2014 - 2025) Analysis & Trends
Regenxbio's Operating Margin history runs 12 years deep, the most recent figure standing at 189.99% for Q4 2025.
- In Q4 2025, Operating Margin rose 5216.0% year-over-year to 189.99%; the TTM figure through Dec 2025 stood at 94.58% (up 18546.0% YoY), while the FY2025 annual figure was 94.58%, up 18546.0% from the prior year.
- Operating Margin was 189.99% for Q4 2025 at Regenxbio, down from 176.27% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 78.66% in Q4 2021 to a low of 408.8% in Q1 2024.
- Historically, Operating Margin has averaged 228.77% across 5 years, with a median of 239.58% in 2021.
- The sharpest annual moves came in 2022 and 2025: Operating Margin sank 26297 bps in 2022, then jumped 42243 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 78.66% in 2021, then slumped by 334 bps to 184.31% in 2022, then plunged by 56 bps to 287.68% in 2023, then increased by 16 bps to 242.14% in 2024, then gained by 22 bps to 189.99% in 2025.
- The last three Operating Margin figures came in at 189.99% (Q4 2025), 176.27% (Q3 2025), and 296.26% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Regenxbio | 315.11 Mn | 85.04 Mn | - | -189.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -189.99% |
| Sep 30, 2025 | -176.27% |
| Jun 30, 2025 | -296.26% |
| Mar 31, 2025 | 13.62% |
| Dec 31, 2024 | -242.14% |
| Sep 30, 2024 | -256.55% |
| Jun 30, 2024 | -251.34% |
| Mar 31, 2024 | -408.80% |
| Dec 31, 2023 | -287.68% |
| Sep 30, 2023 | -224.67% |
| Jun 30, 2023 | -365.96% |
| Mar 31, 2023 | -345.68% |
| Dec 31, 2022 | -184.31% |
| Sep 30, 2022 | -267.97% |
| Jun 30, 2022 | -191.53% |
| Mar 31, 2022 | -321.93% |
| Dec 31, 2021 | 78.66% |
| Sep 30, 2021 | -186.36% |
| Jun 30, 2021 | -237.01% |
| Mar 31, 2021 | -233.22% |